

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	)	
Tae-Yoon Kim et al.	)	Group Art Unit: 1632
Application No.: 10/589,102	)	Examiner, NOBLE, MARCIA
Filed: October 05, 2007	)	STEPHENS
For: THERAPEUTIC USE OF CPG	)	Confirmation No.: 5838
OLIGODEOXYNUCLEOTIDE FOR SKIN		
DISEASE		

## DECLARATION OF DR. Tae-Yoon Kim


Sir:

1. I, Dr. Tae-Yoon Kim, declare the following:
2. I am a citizen of the Republic of Korea, and have the following mailing address: Asia Seonsoochon Apt. #8-702, Jamsil-dong, Songpa-gu, Seoul 138-220, Republic of Korea;
3. I graduated from the Catholic University of Korea, Medical College with M.D. degree in 1980 and Ph.D. degree in 1999;
4. I am a professor of the Department of Dermatology, Catholic University of Korea;
5. I have read and am familiar with the above-identified United States patent application filed April 28, 2006, and I am submitting this Declaration in support of that application;
6. I have performed and/or supervised the experiments reported below.

**< Analysis of Immunoglobulin E (IgE) production in B cells >**


To evaluate inhibitory effect on IgE synthesis in B cells, B cells were stimulated with CD40 (CD154) in presence IL-4 for 5 days. 1 M CpG-ODNs were used for all experiments and ELISA was done with culture supernatants.

As a result, IgE production was reduced by CpG-ODNs treatment.

**<Analysis of Interferon-gamma (IFN- $\gamma$ ) production in splenocyte>**

We investigated effect of CpG-ODNs on IFN- $\gamma$  production. For analysis of IFN- $\gamma$  production, Spleen cells were obtained from DO11.10 mice, which were stimulated with Ovalumin.

The Spleen cells were incubated with or without CpG-ODNs. ELISA assay targeting (IFN- $\gamma$ ) was performed 24 h after stimulation.



7. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date:

Nov. 1, 2010

By:

  
Tae-Yoon Kim